Clinical pharmacokinetics and pharmacogenetics of tamoxifen and endoxifen
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Clinical pharmacokinetics and pharmacogenetics of tamoxifen and endoxifen
Authors
Keywords
-
Journal
Expert Review of Clinical Pharmacology
Volume 12, Issue 6, Pages 523-536
Publisher
Informa UK Limited
Online
2019-04-22
DOI
10.1080/17512433.2019.1610390
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Tamoxifen Pharmacogenetics and Metabolism: Results From the Prospective CYPTAM Study
- (2019) Anabel Sanchez-Spitman et al. JOURNAL OF CLINICAL ONCOLOGY
- Tamoxifen Metabolism and Efficacy in Breast Cancer: A Prospective Multicenter Trial
- (2018) Patrick Neven et al. CLINICAL CANCER RESEARCH
- Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy
- (2018) Matthew P. Goetz et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Therapeutic Drug Monitoring of endoxifen as an alternative for CYP2D6 genotyping in individualizing tamoxifen therapy
- (2018) Aurelia H.M. de Vries Schultink et al. BREAST
- A prospective study on the effect of endoxifen concentration and CYP2D6 phenotypes on clinical outcome in early stage breast cancer patients receiving adjuvant tamoxifen.
- (2018) Anabel Beatriz Sanchez-Spitman et al. JOURNAL OF CLINICAL ONCOLOGY
- 185O_PRSerum assessment of non-adherence to adjuvant endocrine therapy (ET) among premenopausal patients in the prospective multicenter CANTO cohort
- (2018) B Pistilli et al. ANNALS OF ONCOLOGY
- 258PIncidence of clinically significant toxicities in patients with high endoxifen concentrations
- (2018) S L Groenland et al. ANNALS OF ONCOLOGY
- First-in-Human Phase I Study of the Tamoxifen Metabolite Z-Endoxifen in Women With Endocrine-Refractory Metastatic Breast Cancer
- (2017) Matthew P. Goetz et al. JOURNAL OF CLINICAL ONCOLOGY
- Improved Prediction of Endoxifen Metabolism by CYP2D6 Genotype in Breast Cancer Patients Treated with Tamoxifen
- (2017) Werner Schroth et al. Frontiers in Pharmacology
- Impacts of smoking on endocrine treatment response in a prospective breast cancer cohort
- (2016) Mia Persson et al. BRITISH JOURNAL OF CANCER
- Association ofCYP2C19*2and associated haplotypes with lower norendoxifen concentrations in tamoxifen-treated Asian breast cancer patients
- (2016) Joanne Siok Liu Lim et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Pharmacogenetics of UGT1A4, UGT2B7 and UGT2B15 and Their Influence on Tamoxifen Disposition in Asian Breast Cancer Patients
- (2016) Natalia Sutiman et al. CLINICAL PHARMACOKINETICS
- Endocrine Therapy for Hormone Receptor–Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline
- (2016) Hope S. Rugo et al. JOURNAL OF CLINICAL ONCOLOGY
- Treatment Adherence and Its Impact on Disease-Free Survival in the Breast International Group 1-98 Trial of Tamoxifen and Letrozole, Alone and in Sequence
- (2016) Jacquie H. Chirgwin et al. JOURNAL OF CLINICAL ONCOLOGY
- Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2015) E. Senkus et al. ANNALS OF ONCOLOGY
- Circadian variation in tamoxifen pharmacokinetics in mice and breast cancer patients
- (2015) Lisette Binkhorst et al. BREAST CANCER RESEARCH AND TREATMENT
- CYP2D6 genotype- and endoxifen-guided tamoxifen dose escalation increases endoxifen serum concentrations without increasing side effects
- (2015) V. O. Dezentjé et al. BREAST CANCER RESEARCH AND TREATMENT
- Global Cancer Incidence and Mortality Rates and Trends--An Update
- (2015) L. A. Torre et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Augmentation of Endoxifen Exposure in Tamoxifen-Treated Women Following SSRI Switch
- (2015) Lisette Binkhorst et al. CLINICAL PHARMACOKINETICS
- Age-Related Changes in Hepatic Function: An Update on Implications for Drug Therapy
- (2015) Joseph L. Tan et al. DRUGS & AGING
- Tamoxifen and Antidepressant Drug Interaction in a Cohort of 16 887 Breast Cancer Survivors
- (2015) Reina Haque et al. JNCI-Journal of the National Cancer Institute
- Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials
- (2015) LANCET
- Estrogen receptors in breast carcinogenesis and endocrine therapy
- (2015) Bo Huang et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- CYP3A4*22is related to increased plasma levels of 4-hydroxytamoxifen and partially compensates for reduced CYP2D6 activation of tamoxifen
- (2015) Marina Venzon Antunes et al. PHARMACOGENOMICS
- Impacts of the Glucuronidase Genotypes UGT1A4, UGT2B7, UGT2B15 and UGT2B17 on Tamoxifen Metabolism in Breast Cancer Patients
- (2015) Alicia Romero-Lorca et al. PLoS One
- Influence of CYP2D6 and CYP3A4 Phenotypes, Drug Interactions, and Vitamin D Status on Tamoxifen Biotransformation
- (2015) Marina V. Antunes et al. THERAPEUTIC DRUG MONITORING
- Tamoxifen and Antidepressant Drug Interaction in a Cohort of 16 887 Breast Cancer Survivors
- (2015) Reina Haque et al. JNCI-Journal of the National Cancer Institute
- Menopause
- (2015) Susan R. Davis et al. Nature Reviews Disease Primers
- Adjusting the dose of tamoxifen in patients with early breast cancer and CYP2D6 poor metabolizer phenotype
- (2014) Eduardo Martinez de Dueñas et al. BREAST
- Active cigarette smoking and the risk of breast cancer: a cohort study
- (2014) Chelsea Catsburg et al. Cancer Epidemiology
- Adherence to Endocrine Therapy in Breast Cancer Adjuvant and Prevention Settings
- (2014) R. T. Chlebowski et al. Cancer Prevention Research
- Active cigarette smoking and risk of breast cancer
- (2014) Chelsea Catsburg et al. INTERNATIONAL JOURNAL OF CANCER
- Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update
- (2014) Harold J. Burstein et al. JOURNAL OF CLINICAL ONCOLOGY
- Loss of Heterozygosity at the CYP2D6 Locus in Breast Cancer: Implications for Germline Pharmacogenetic Studies
- (2014) Matthew P. Goetz et al. JNCI-Journal of the National Cancer Institute
- In vitro cytotoxicity of 4′-OH-tamoxifen and estradiol in human endometrial adenocarcinoma cells HEC-1A and HEC-1B
- (2014) MARIA E. CUEVAS et al. ONCOLOGY REPORTS
- Tamoxifen metabolism predicts drug concentrations and outcome in premenopausal patients with early breast cancer
- (2014) P Saladores et al. PHARMACOGENOMICS JOURNAL
- How often did Belgian physicians co-prescribe tamoxifen with strong CYP2D6 inhibitors over the last 6 years?
- (2014) A. S. Dieudonné et al. ACTA CLINICA BELGICA
- Prevalence of Depression in Breast Cancer Survivors: a Systematic Review of Observational Studies
- (2013) Nor Zuraida Zainal et al. Asian Pacific Journal of Cancer Prevention
- Impact of SERM adherence on treatment effect: International Breast Cancer Study Group Trials 13-93 and 14-93
- (2013) Olivia Pagani et al. BREAST CANCER RESEARCH AND TREATMENT
- CYP3A4 and seasonal variation in vitamin D status in addition to CYP2D6 contribute to therapeutic endoxifen level during tamoxifen therapy
- (2013) Wendy A. Teft et al. BREAST CANCER RESEARCH AND TREATMENT
- Unjustified prescribing of CYP2D6 inhibiting SSRIs in women treated with tamoxifen
- (2013) Lisette Binkhorst et al. BREAST CANCER RESEARCH AND TREATMENT
- CYP2D6 genotype in relation to tamoxifen efficacy in a Dutch cohort of the tamoxifen exemestane adjuvant multinational (TEAM) trial
- (2013) V. O. Dezentjé et al. BREAST CANCER RESEARCH AND TREATMENT
- Serum concentrations of tamoxifen and its metabolites increase with age during steady-state treatment
- (2013) Ernst A. Lien et al. BREAST CANCER RESEARCH AND TREATMENT
- Prediction of tamoxifen outcome by genetic variation of CYP2D6 in post-menopausal women with early breast cancer
- (2013) Hiltrud Brauch et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- CYP2D6 Genotype and Adjuvant Tamoxifen: Meta-Analysis of Heterogeneous Study Populations
- (2013) M A Province et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Clinical consequences of polypharmacy in elderly
- (2013) Robert L Maher et al. Expert Opinion On Drug Safety
- Synthesis of Mixed (E,Z)-, (E)-, and (Z)-Norendoxifen with Dual Aromatase Inhibitory and Estrogen Receptor Modulatory Activities
- (2013) Wei Lv et al. JOURNAL OF MEDICINAL CHEMISTRY
- PharmGKB summary
- (2013) Daniel J. Klein et al. Pharmacogenetics and Genomics
- Endoxifen’s Molecular Mechanisms of Action Are Concentration Dependent and Different than That of Other Anti-Estrogens
- (2013) John R. Hawse et al. PLoS One
- Relationship between Genotypes Sult1a2 and Cyp2d6 and Tamoxifen Metabolism in Breast Cancer Patients
- (2013) Ana Fernández-Santander et al. PLoS One
- CYP2D6 genotypes, endoxifen levels, and disease recurrence in 224 Filipino and Vietnamese women receiving adjuvant tamoxifen for operable breast cancer
- (2013) Richard R Love et al. SpringerPlus
- Trends in co-prescribing of antidepressants and tamoxifen among women with breast cancer, 2004–2010
- (2012) Stacie B. Dusetzina et al. BREAST CANCER RESEARCH AND TREATMENT
- Tissue distribution of 4-hydroxy-N-desmethyltamoxifen and tamoxifen-N-oxide
- (2012) Jennifer Gjerde et al. BREAST CANCER RESEARCH AND TREATMENT
- Adherence and discontinuation of adjuvant hormonal therapy in breast cancer patients: a population-based study
- (2012) Annette Wigertz et al. BREAST CANCER RESEARCH AND TREATMENT
- Adjuvant therapy with tamoxifen compared to aromatase inhibitors for 257 male breast cancer patients
- (2012) Holm Eggemann et al. BREAST CANCER RESEARCH AND TREATMENT
- The use of the 13C-dextromethorphan breath test for phenotyping CYP2D6 in breast cancer patients using tamoxifen: association with CYP2D6 genotype and serum endoxifen levels
- (2012) F. L. Opdam et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Tamoxifen Use in Postmenopausal Breast Cancer: CYP2D6 Matters
- (2012) Hiltrud Brauch et al. JOURNAL OF CLINICAL ONCOLOGY
- Re: CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women With Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial and Re: CYP2D6 and UGT2B7 Genotype and Risk of Recurrence in Tamoxifen-Treated Breast Cancer Patients
- (2012) P. D. P. Pharoah et al. JNCI-Journal of the National Cancer Institute
- Re: CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women With Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial
- (2012) Y. Nakamura et al. JNCI-Journal of the National Cancer Institute
- Re: CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women With Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial
- (2012) V. Stanton JNCI-Journal of the National Cancer Institute
- CYP2D6 and UGT2B7 Genotype and Risk of Recurrence in Tamoxifen-Treated Breast Cancer Patients
- (2012) James M. Rae et al. JNCI-Journal of the National Cancer Institute
- CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women with Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial
- (2012) Meredith M. Regan et al. JNCI-Journal of the National Cancer Institute
- The tamoxifen metabolite norendoxifen is a potent and selective inhibitor of aromatase (CYP19) and a potential lead compound for novel therapeutic agents
- (2011) Wenjie Jessie Lu et al. BREAST CANCER RESEARCH AND TREATMENT
- Functional Polymorphisms in UDP-Glucuronosyl Transferases and Recurrence in Tamoxifen-Treated Breast Cancer Survivors
- (2011) T. P. Ahern et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Activity Levels of Tamoxifen Metabolites at the Estrogen Receptor and the Impact of Genetic Polymorphisms of Phase I and II Enzymes on Their Concentration Levels in Plasma
- (2011) T E Mürdter et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Tamoxifen Metabolite Concentrations, CYP2D6 Genotype, and Breast Cancer Outcomes
- (2011) L Madlensky et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- SULT1A1,CYP2C19and disease-free survival in early breast cancer patients receiving tamoxifen
- (2011) Ann M Moyer et al. PHARMACOGENOMICS
- Orally administered Endoxifen is a new therapeutic agent for breast cancer
- (2010) Ateeq Ahmad et al. BREAST CANCER RESEARCH AND TREATMENT
- An ultra performance liquid chromatography–tandem MS assay for tamoxifen metabolites profiling in plasma: First evidence of 4′-hydroxylated metabolites in breast cancer patients
- (2010) E. Dahmane et al. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES
- Obesity and Hormone Therapy in Breast Cancer: An Unfinished Puzzle
- (2010) Pamela J. Goodwin et al. JOURNAL OF CLINICAL ONCOLOGY
- Effect of Concomitant CYP2D6 Inhibitor Use and Tamoxifen Adherence on Breast Cancer Recurrence in Early-Stage Breast Cancer
- (2010) Vincent O. Dezentjé et al. JOURNAL OF CLINICAL ONCOLOGY
- Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial
- (2010) Jack Cuzick et al. LANCET ONCOLOGY
- The Tamoxifen Metabolite, Endoxifen, Is a Potent Antiestrogen that Targets Estrogen Receptor for Degradation in Breast Cancer Cells
- (2009) X. Wu et al. CANCER RESEARCH
- Functional Significance of UDP-Glucuronosyltransferase Variants in the Metabolism of Active Tamoxifen Metabolites
- (2009) A. S. Blevins-Primeau et al. CANCER RESEARCH
- Pharmacogenomics of Tamoxifen Therapy
- (2009) H. Brauch et al. CLINICAL CHEMISTRY
- Sex Differences in Pharmacokinetics and Pharmacodynamics
- (2009) Offie P. Soldin et al. CLINICAL PHARMACOKINETICS
- Intestinal glucuronidation metabolism may have a greater impact on oral bioavailability than hepatic glucuronidation metabolism in humans: A study with raloxifene, substrate for UGT1A1, 1A8, 1A9, and 1A10
- (2009) Takashi Mizuma INTERNATIONAL JOURNAL OF PHARMACEUTICS
- Association Between CYP2D6 Polymorphisms and Outcomes Among Women With Early Stage Breast Cancer Treated With Tamoxifen
- (2009) Werner Schroth JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Genotype-guided tamoxifen therapy: time to pause for reflection?
- (2009) Timothy L Lash et al. LANCET ONCOLOGY
- The changing prevalence of comorbidity across the age spectrum
- (2008) Jay F. Piccirillo et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation